Is DA-1726 Approved? Early Status and Oxyntomodulin Timeline (2026)
No. DA-1726 is still a Phase 1 asset. It is an early obesity story with mechanism intrigue, not a near-term launch candidate.
Current stage
Phase 1
Approval read
Not approved.
Likely window
2029 or later if the program matures successfully.
Next step
Generate early human data that proves the mechanism deserves more serious follow-on development.
Direct answer
No. DA-1726 is still a Phase 1 asset. It is an early obesity story with mechanism intrigue, not a near-term launch candidate.
Status facts for search and AI answers
What this DA-1726 status page answers
Compound
DA-1726
DA-1726 is tracked as a Oxyntomodulin (GLP-1/GCG) program from NeuroBo.
Approval read
Not approved.
No. DA-1726 is still a Phase 1 asset. It is an early obesity story with mechanism intrigue, not a near-term launch candidate.
Likely window
2029 or later if the program matures successfully.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Generate early human data that proves the mechanism deserves more serious follow-on development.
This is the milestone most likely to change the page's answer.
Decision path
What does DA-1726's status mean for access?
DA-1726's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- DA-1726
- Stage
- Phase 1
- Approval read
- Not approved.
- Window
- 2029 or later if the program matures successfully.
Step 1
Classify availability
Phase 1 oxyntomodulin-style program with an early-stage timeline and a lot of proof still ahead.
Read compound pageStep 2
Watch required milestone
Generate early human data that proves the mechanism deserves more serious follow-on development.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 1 oxyntomodulin-style program with an early-stage timeline and a lot of proof still ahead.
DA-1726 matters because early glucagon-linked and oxyntomodulin-style assets can widen the field if the data stays credible.
What needs to happen next
Generate early human data that proves the mechanism deserves more serious follow-on development.
What FormBlends is watching
- Whether early readouts justify a stronger development case
- How the sponsor frames the mechanism relative to better-known assets
- Whether the market gives it meaningful attention
What could delay the timeline
- Early-stage attrition
- A mechanism story that gets lost in a crowded glucagon-linked field
- Limited sponsor scale